XML 13 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Balance Sheets - USD ($)
Mar. 31, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 2,767,780 $ 7,507,659
Short-term investments available-for-sale, at fair value 2,610,828 4,304,901
Accounts receivable 1,196,129 1,377,441
Inventory, net of allowance of $274,130 at March 31, 2017 and $270,307 at December 31, 2016 1,255,428 1,511,053
Prepaid expenses and other 368,563 433,328
Total current assets 8,198,728 15,134,382
Deferred offering costs 115,062 49,630
Property and equipment, net 3,083,793 3,270,197
Total assets 11,397,583 18,454,209
Current liabilities:    
Accounts payable 1,193,217 761,663
Accrued liabilities 1,281,947 1,670,286
Deferred revenue 255,477 335,659
NuvoGen obligation - current 557,634 604,751
Term loan payable - current 6,527,795 6,389,782
Other current liabilities 241,274 258,850
Total current liabilities 10,057,344 10,020,991
Term loan payable - non-current, net of discount and debt issuance costs 3,827,095 5,389,137
NuvoGen obligation - non-current, net of discount 7,914,597 8,017,356
Other non-current liabilities 560,772 619,587
Total liabilities 22,359,808 24,047,071
Commitments and Contingencies
Stockholders’ deficit:    
Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2017 and December 31, 2016, 8,060,687 shares issued and outstanding, at March 31, 2017, 7,939,967 and 7,938,571 shares issued and outstanding, respectively, at December 31, 2016 8,059 7,938
Additional paid-in-capital 110,452,770 110,081,334
Treasury stock, 0 shares as of March 31, 2017 and 1,396 shares as of December 31, 2016   (75,000)
Accumulated other comprehensive loss (736) (1,090)
Accumulated deficit (121,422,318) (115,606,044)
Total stockholders’ deficit (10,962,225) (5,592,862)
Total liabilities and stockholders' deficit $ 11,397,583 $ 18,454,209